Allos Therapeutics, Inc.

210 articles about Allos Therapeutics, Inc.

• Allos Therapeutics, Inc. Release: Retrospective Analysis Finds EFAPROXYN(TM) Extends Survival With Quality Of Life In Patients With Brain Metastases Originating From Breast Cancer

  12/12/2005

• Allos Therapeutics, Inc. Release: PDX Shows Promising Activity In Patients With Resistant T-Cell Lymphomas

  12/12/2005

• Allos Therapeutics, Inc. Release: Interim Phase 1 Data On RH1 Presented At AACR-NCI-EORTC Conference

  11/17/2005

• Allos Therapeutics, Inc. Appoints Timothy P. Lynch To Board Of Directors

  11/17/2005

• Allos Therapeutics, Inc. Release: Data From Phase 1 Clinical Trial Of PDX (Pralatrexate) To Be Presented At American Society of Hematology Annual Meeting

  11/16/2005

• Allos Therapeutics, Inc. Reports Third Quarter 2005 Financial Results

  11/9/2005

• Allos Therapeutics, Inc. Release: Data On EFAPROXYN(TM) And RH1 To Be Presented At Upcoming Scientific Conferences

  11/8/2005

• Allos Therapeutics, Inc. Announces Dismissal Of Securities Class Action Lawsuit

  10/21/2005

• Allos Therapeutics, Inc. Reports First Quarter 2005 Financial Results

  5/5/2005

• Surviving Biotech's Downturns

  8/18/2004